• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丹麦多发性硬化症患者的生存率:一项全国性长期流行病学调查。

Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey.

作者信息

Brønnum-Hansen H, Koch-Henriksen N, Hyllested K

机构信息

Danish Institute for Clinical Epidemiology, Copenhagen.

出版信息

Neurology. 1994 Oct;44(10):1901-7. doi: 10.1212/wnl.44.10.1901.

DOI:10.1212/wnl.44.10.1901
PMID:7936244
Abstract

We estimated survival probability and excess death rates for patients with MS on the basis of data from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark (population, five million) since 1948. We reviewed and reclassified all case records according to standardized diagnostic criteria. By linkage to the Danish Central Population Registry, we lost to follow-up only 25 patients who had emigrated. The median survival time from onset of the disease was 28 years in men (compared with 40 years in the matched general male population) and 33 years in women (versus 46 years). The median survival time from diagnosis was 22 years in men (versus 37 years) and 28 years in women (versus 42 years). The excess death rate between onset and follow-up (observed deaths per 1,000 person-years minus the expected number of deaths in a matched general population) was 14.3 in men, which was significantly higher than in women (12.0). Excess mortality increased with age at onset of MS in people of each sex. The 10-year excess death rate has decreased significantly in recent decades. Excess mortality was highest in cases with cerebellar symptoms at onset.

摘要

我们根据丹麦多发性硬化症登记处的数据估算了多发性硬化症患者的生存概率和超额死亡率,该登记处收录了自1948年以来丹麦(人口500万)几乎所有被诊断为多发性硬化症的患者。我们根据标准化诊断标准对所有病例记录进行了复查和重新分类。通过与丹麦中央人口登记处的数据关联,我们仅失访了25名移民患者。疾病发病后的中位生存时间,男性为28年(与之匹配的普通男性人群为40年),女性为33年(与之匹配的普通女性人群为46年)。诊断后的中位生存时间,男性为22年(与之匹配的普通男性人群为37年),女性为28年(与之匹配的普通女性人群为42年)。发病至随访期间的超额死亡率(每1000人年观察到的死亡人数减去与之匹配的普通人群中预期的死亡人数),男性为14.3,显著高于女性(12.0)。各性别中,多发性硬化症发病时的超额死亡率均随年龄增长而升高。近几十年来,10年超额死亡率显著下降。发病时伴有小脑症状的病例超额死亡率最高。

相似文献

1
Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey.丹麦多发性硬化症患者的生存率:一项全国性长期流行病学调查。
Neurology. 1994 Oct;44(10):1901-7. doi: 10.1212/wnl.44.10.1901.
2
[Survival in disseminated sclerosis in Denmark. A nation-wide study of the period 1948-1986].[丹麦播散性硬化症的生存率。1948 - 1986年全国性研究]
Ugeskr Laeger. 1995 Dec 18;157(51):7131-5.
3
Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.丹麦多发性硬化症患者的超额死亡率在过去六十年中显著下降:一项基于人群的研究。
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):626-631. doi: 10.1136/jnnp-2017-315907.
4
Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey.视神经炎作为多发性硬化症的首发表现:一项全国性长期调查
Neurology. 1999 Aug 11;53(3):473-8. doi: 10.1212/wnl.53.3.473.
5
Trends in survival and cause of death in Danish patients with multiple sclerosis.丹麦多发性硬化症患者的生存趋势及死因
Brain. 2004 Apr;127(Pt 4):844-50. doi: 10.1093/brain/awh104. Epub 2004 Feb 11.
6
Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.丹麦成骨不全患者的死亡率和发病率。
Dan Med J. 2018 Apr;65(4).
7
The Danish Multiple Sclerosis Registry: a 50-year follow-up.丹麦多发性硬化症登记处:50年随访
Mult Scler. 1999 Aug;5(4):293-6. doi: 10.1177/135245859900500418.
8
Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada.多发性硬化症的相对死亡率和生存率:来自加拿大不列颠哥伦比亚省的发现。
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):61-6. doi: 10.1136/jnnp-2011-300616. Epub 2011 Aug 23.
9
Long-term survival experience of patients with multiple sclerosis.多发性硬化症患者的长期生存经验。
J Insur Med. 1997;29(2):101-6.
10
Survival and mortality rates among Danes with MS.
Int MS J. 2006 May;13(2):66-71.

引用本文的文献

1
Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.稳定的多发性硬化症队列患者超额死亡率,该队列于 1970-2010 年确诊。
Eur J Neurol. 2024 Dec;31(12):e16480. doi: 10.1111/ene.16480. Epub 2024 Sep 11.
2
Global Assessment of Palliative Care Need: Serious Health-Related Suffering Measurement Methodology.全球姑息治疗需求评估:严重健康相关痛苦测量方法学。
J Pain Symptom Manage. 2024 Aug;68(2):e116-e137. doi: 10.1016/j.jpainsymman.2024.03.027. Epub 2024 Apr 16.
3
Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis.
专科药房护理对多发性硬化症健康结局的影响。
Am Health Drug Benefits. 2016 Nov;9(8):420-429.
4
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.多发性硬化症的结果谱:残疾、死亡率以及一组起病时的预测因素。
J Neurol. 2015 May;262(5):1148-63. doi: 10.1007/s00415-015-7674-y. Epub 2015 Feb 26.
5
Mortality in patients with multiple sclerosis.多发性硬化症患者的死亡率。
Neurology. 2013 Jul 9;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388.
6
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.国家、性别、EDSS 变化和治疗选择独立预测多发性硬化症和临床孤立综合征的治疗中断。
PLoS One. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29.
7
Validation of the danish version of functional assessment of multiple sclerosis: a quality of life instrument.丹麦版多发性硬化症功能评估量表的验证:一种生活质量工具
Mult Scler Int. 2011;2011:121530. doi: 10.1155/2011/121530. Epub 2011 Oct 30.
8
Clinical prognostic factors in multiple sclerosis: a natural history review.多发性硬化症的临床预后因素:自然病史回顾。
Nat Rev Neurol. 2009 Dec;5(12):672-82. doi: 10.1038/nrneurol.2009.178.
9
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.Campath 1-H治疗侵袭性复发缓解型多发性硬化症患者。
J Neurol. 2008 Feb;255(2):231-8. doi: 10.1007/s00415-008-0696-y. Epub 2008 Feb 20.
10
Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis.多发性硬化症TMEV动物模型中的伤害感受、性别与外周神经支配分析
Pain. 2008 Jun;136(3):293-304. doi: 10.1016/j.pain.2007.07.007. Epub 2007 Sep 4.